Medindia LOGIN REGISTER
Medindia

Preventing Scar Tissue After Heart Attack With Hydrogel Therapy

by Dr. Jayashree Gopinath on Mar 13 2023 9:52 PM
Listen to this article
0:00/0:00

 Preventing Scar Tissue After Heart Attack With Hydrogel Therapy
A novel hydrogel biomaterial that will prevent scar tissue from forming in the heart following a heart attack will be validated by the European Consortium-sponsored ELR-Scar project. Myocardial infarction (MI), or heart attack, happens as a result of ischaemic heart disease (IHD). Europe has the highest rates of IHD worldwide, equalling almost 26.5 million patients.
In the days and weeks following a heart attack, the damaged cells of the heart are replaced by scar tissue. This scarring or 'remodeling 'of the heart tissue can cause further dysfunction and complications for the patient. Hence, there is a clear medical need for new treatment solutions that can prevent scar tissue formation and irreversible cardiac remodeling.

Hydrogel Could Repair Heart Muscle After Heart Attacks

Researchers hope that this hydrogel will do exactly that to fundamentally improve clinical practice. They have recently received the prestigious George Winter Award 2022 from the European Society for Biomaterials. The consortium includes seven industry and academic partners across Ireland, Spain, Belgium, Germany, Lithuania, Poland, and the Netherlands.

The hydrogel solution being developed by the team is bispecific, which means that its properties or activities vary according to the specific biological molecule it interacts with. It will have enhanced adhesion to cardiac tissue and is made of a degradable biomaterial that would be administered to the patient through an intravenous, endocardial catheter.

This EU funding recognizes the importance of tackling economic and personal health burdens and adds to the €70 million in EU investment generated by CÚRAM researchers during its first eight years. ELR-SCAR draws on collaborations across Western and Eastern European countries to work on the project's regulatory, manufacturing, and clinical need.



Source-Newswise


Advertisement